Prognostic Utility of a Modified HEART Score When Different Troponin Cut Points Are Used.
Journal
Critical pathways in cardiology
ISSN: 1535-2811
Titre abrégé: Crit Pathw Cardiol
Pays: United States
ID NLM: 101165286
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
15
5
2021
medline:
9
11
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
Although the recommended cut point for cardiac troponin (cTn) is the 99th percentile, many institutions use cut points that are multiples higher than the 99th percentile for diagnosing acute myocardial infarction (AMI). Prior studies have shown that patients with a HEART score (HS) ≤ 3 and normal serial cTn values (modified HS) are at low risk for adverse events. This study aimed to evaluate the prognostic utility of the HS when various cTn cut points are used. This was a substudy of High Sensitivity Cardiac Troponin T assay for RAPID Rule-out of Acute Myocardial Infarction (TRAPID-AMI), a multicenter, international trial evaluating a rapid rule-out AMI study using high-sensitivity cardiac troponin T (hs-cTnT). One-thousand two-hundred eighty-two patients were evaluated for AMI from 12 centers in Europe, United States, and Australia from 2011 to 2013. Blood samples of hs-cTnT were collected at presentation and 2 hours, and each patient had a HS calculated. The US Food and Drug Administration approved 99th percentile for hs-cTnT (19 ng/L) was used. There were 213 (17%) AMIs. Within 30 days, there were an additional 2 AMIs and 8 deaths. The adverse event rates at 30 days (death/AMI) for a HS ≤ 3 and nonelevated hs-cTnT over 2 hours using increasing hs-cTnT cut points ranged from 0.6% to 5.1%. Using the recommended 99th percentile cut point for hs-cTnT, the combination of a HS ≤ 3 with nonelevated hs-cTnT values over 2 hours identifies a low-risk cohort who can be considered for discharge from the emergency department without further testing. The prognostic utility of this strategy is greatly lessened as higher hs-cTnT cut points are used.
Sections du résumé
BACKGROUND
Although the recommended cut point for cardiac troponin (cTn) is the 99th percentile, many institutions use cut points that are multiples higher than the 99th percentile for diagnosing acute myocardial infarction (AMI). Prior studies have shown that patients with a HEART score (HS) ≤ 3 and normal serial cTn values (modified HS) are at low risk for adverse events. This study aimed to evaluate the prognostic utility of the HS when various cTn cut points are used.
METHODS
This was a substudy of High Sensitivity Cardiac Troponin T assay for RAPID Rule-out of Acute Myocardial Infarction (TRAPID-AMI), a multicenter, international trial evaluating a rapid rule-out AMI study using high-sensitivity cardiac troponin T (hs-cTnT). One-thousand two-hundred eighty-two patients were evaluated for AMI from 12 centers in Europe, United States, and Australia from 2011 to 2013. Blood samples of hs-cTnT were collected at presentation and 2 hours, and each patient had a HS calculated. The US Food and Drug Administration approved 99th percentile for hs-cTnT (19 ng/L) was used.
RESULTS
There were 213 (17%) AMIs. Within 30 days, there were an additional 2 AMIs and 8 deaths. The adverse event rates at 30 days (death/AMI) for a HS ≤ 3 and nonelevated hs-cTnT over 2 hours using increasing hs-cTnT cut points ranged from 0.6% to 5.1%.
CONCLUSIONS
Using the recommended 99th percentile cut point for hs-cTnT, the combination of a HS ≤ 3 with nonelevated hs-cTnT values over 2 hours identifies a low-risk cohort who can be considered for discharge from the emergency department without further testing. The prognostic utility of this strategy is greatly lessened as higher hs-cTnT cut points are used.
Identifiants
pubmed: 33988541
doi: 10.1097/HPC.0000000000000262
pii: 00132577-202109000-00004
doi:
Substances chimiques
Biomarkers
0
Troponin
0
Troponin T
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-139Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127:749–756.
Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
Owens PL, Barrett ML, Gibson TB, et al. Emergency department care in the United States: a profile of national data sources. Ann Emerg Med. 2010;56:150–165.
Goodacre S, Cross E, Arnold J, et al. The health care burden of acute chest pain. Heart. 2005;91:229–230.
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000;342:1163–1170.
Vasile VC, Jaffe AS. High-sensitivity cardiac troponin for the diagnosis of patients with acute coronary syndromes. Curr Cardiol Rep. 2017;19:92.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237–269.
Anand A, Shah ASV, Beshiri A, et al. Global adoption of high-sensitivity cardiac troponins and the universal definition of myocardial infarction. Clin Chem. 2019;65:484–489.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–e228.
Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011;305:1210–1216.
Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ. 2012;344:e1533.
Bagai A, Alexander KP, Berger JS, et al. Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. Am Heart J. 2017;190:135–139.
Hachey BJ, Kontos MC, Newby LK, et al. Trends in use of biomarker protocols for the evaluation of possible myocardial infarction. J Am Heart Assoc. 2017;6:e005852.
Collinson P, Hammerer-Lercher A, Suvisaari J, et al.; Working Group for Cardiac Markers, European Federation of Clinical Chemistry and Laboratory Medicine. How well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the CARdiac MArker Guidelines Uptake in Europe study (CARMAGUE). Clin Chem. 2016;62:1264–1271.
Poldervaart JM, Langedijk M, Backus BE, et al. Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department. Int J Cardiol. 2017;227:656–661.
McCord J, Cabrera R, Lindahl B, et al.; TRAPID-AMI Investigators. Prognostic utility of a modified HEART score in chest pain patients in the emergency department. Circ Cardiovasc Qual Outcomes. 2017;10:e003101.
Mueller C, Giannitsis E, Christ M, et al.; TRAPID-AMI Investigators. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. Ann Emerg Med. 2016;68:76–87.e4.
Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:254–261.
Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58:628–637.
Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014;35:552–556.
Thygesen K, Alpert JS, Jaffe AS, et al.; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Glob Heart. 2012;7:275–295.
Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124:136–145.
Six AJ, Cullen L, Backus BE, et al. The HEART score for the assessment of patients with chest pain in the emergency department: a multinational validation study. Crit Pathw Cardiol. 2013;12:121–126.
Santi L, Farina G, Gramenzi A, et al. The HEART score with high-sensitive troponin T at presentation: ruling out patients with chest pain in the emergency room. Intern Emerg Med. 2017;12:357–364.
Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979;300:1350–1358.
Wu AHB, Christenson R. The era for high-sensitivity cardiac troponin has begun in the US (finally). J Appl Lab Med. 2017;2:1–3.
Twerenbold R, Boeddinghaus J, Nestelberger T, et al. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction. J Am Coll Cardiol. 2017;70:996–1012.
Amsterdam EA, Kirk JD, Bluemke DA, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, and Interdisciplinary Council on Quality of Care and Outcomes Research. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation. 2010;122:1756–1776.
Than M, Herbert M, Flaws D, et al. What is an acceptable risk of major adverse cardiac event in chest pain patients soon after discharge from the emergency department?: A clinical survey. Int J Cardiol. 2013;166:752–754.
Baugh CW, Greenberg JO, Mahler SA, et al. Implementation of a risk stratification and management pathway for acute chest pain in the emergency department. Crit Pathw Cardiol. 2016;15:131–137.
Wang H, Watson K, Robinson RD, et al. Chest pain risk scores can reduce emergent cardiac imaging test needs with low major adverse cardiac events occurrence in an emergency department observation unit. Crit Pathw Cardiol. 2016;15:145–151.
Melki D, Jernberg T. HEART score: a simple and useful tool that may lower the proportion of chest pain patients who are admitted. Crit Pathw Cardiol. 2013;12:127–131.
Mahler SA, Riley RF, Hiestand BC, et al. The HEART pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes. 2015;8:195–203.
Mahler SA, Hiestand BC, Goff DC Jr, et al. Can the HEART score safely reduce stress testing and cardiac imaging in patients at low risk for major adverse cardiac events? Crit Pathw Cardiol. 2011;10:128–133.
Mahler SA, Miller CD, Hollander JE, et al. Identifying patients for early discharge: performance of decision rules among patients with acute chest pain. Int J Cardiol. 2013;168:795–802.
Sandoval Y, Nowak R, deFilippi CR, et al. Myocardial infarction risk stratification with a single measurement of high-sensitivity troponin I. J Am Coll Cardiol. 2019;74:271–282.
Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2015;68:1125.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med. 2019;380:2529–2540.
Wu AHB, Christenson RH, Greene DN, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018;64:645–655.